Low Sodium Oxybate in Patients With Idiopathic Hypersomnia
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
Low sodium oxybate has been approved by the U.S. Food and Drug Administration (FDA) for the
treatment of idiopathic hypersomnia. In this study, the researchers want to learn how low
sodium oxybate impacts ability of people diagnosed with idiopathic hypersomnia to sleep for
long periods of time. In addition, this study will use novel tools to determine when an
individual is awake or asleep.